Currently, patients with advanced cSCC are primarily treated with immunotherapy, specifically the immune checkpoint inhibitors targeting the PD1/PDL1 axis, when surgery or radiotherapy is no longer viable [60,61]. The gene discussed is CD274; the disease is skin squamous cell carcinoma.